Analyst Research

Report Title Price
Provider: Jefferson Research
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Salix Pharmaceuticals Ltd Reiterates FY 2013 Revenue Guidance-Conference Call

Wednesday, 5 Jun 2013 01:30pm EDT 

Salix Pharmaceuticals Ltd reiterated its guidance for fiscal 2013 and expects $920 million in revenue. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $920 million for fiscal 2013. 

Company Quote

4.86 +3.59%
4:00pm EDT